---
title: "AN2 Therapeutics, Inc. (ANTX.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ANTX.US.md"
symbol: "ANTX.US"
name: "AN2 Therapeutics, Inc."
industry: "制藥"
---

# AN2 Therapeutics, Inc. (ANTX.US)

| Item | Detail |
|------|--------|
| Industry | 制藥 |
| Location | 美股市場 |
| Website | [www.an2therapeutics.com](https://www.an2therapeutics.com) |

## Company Profile

AN2 Therapeutics, Inc.是一家生物制藥公司，專注于發現和開發新型小分子治療藥物。該公司的初始候選藥物包括 epetraborole，目前正在進行針對非結核分枝桿菌肺病患者的每日一次口服治療的三期臨床試驗，同時也在研究用于急性美利堅病的治療。它還開發了 AN2-502998（AN15368），這是一種基于硼的小分子，正在進行慢性恰加斯病的臨床前試驗；並且有多個研究項目，旨在基于其硼化學平台開發新型化合物，針對腫瘤學和傳染病的治療。該公司與 Anacor Pharmaceuticals, Inc.簽訂了許可協議

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.85 | 97/256 | - | - | - |
| PB | 0.48 | 20/256 | 0.51 | 0.48 | 0.44 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-01-12T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 0 | 0% |
| Overweight | 0 | 0% |
| Hold | 1 | 100% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.06 |
| Highest Target | 1.00 |
| Lowest Target | 1.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/ANTX.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ANTX.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ANTX.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.